Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

Reumatol Clin (Engl Ed). 2021 Nov;17(9):556-557. doi: 10.1016/j.reumae.2020.03.005.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • COVID-19 Drug Treatment*
  • Cyclosporine / therapeutic use*
  • Cytokine Release Syndrome / drug therapy
  • Cytokine Release Syndrome / immunology
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • SARS-CoV-2 / physiology

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Cyclosporine
  • tocilizumab